Results 341 to 350 of about 1,468,461 (396)
Some of the next articles are maybe not open access.
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Ralf Lutterbüse +2 more
openaire +3 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
Bert J.E.G. Bast, David M. Segal
openaire +3 more sources
The manufacturing considerations of bispecific antibodies
Expert Opinion on Biological Therapy, 2022Introduction Antibody therapies have made huge strides in providing safe and efficacious drugs for autoimmune, cancer, and infectious diseases. These bispecific antibodies can be assembled from the basic building blocks of IgGs, resulting in dozens of ...
D. Underwood, J. Bettencourt, Z. Jawad
semanticscholar +1 more source
Pharmacokinetics of Bispecific Antibody
Current Pharmacology Reports, 2017This article provides a brief overview of bispecific antibody (BsAb) mechanisms of action, structures, and pharmacokinetic (PK) properties, including absorption, distribution, and elimination. Recent trend in BsAb development is also introduced from a PK perspective.
Yang Chen, Yan Xu
openaire +2 more sources
Immunotherapeutic perspective for bispecific antibodies
Immunology Today, 2000Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
Annemiek B. van Spriel +2 more
openaire +3 more sources
Catumaxomab: A bispecific trifunctional antibody
Drugs of Today, 2009The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
Marcus Schmidt +3 more
openaire +3 more sources
Targeting cancer with bispecific antibodies [PDF]
Science, 2021 Bispecific antibodies might provide off-the-shelf immunotherapeutics for treating ...
openaire +2 more sources
Bispecific antibodies for delivery into the brain
Current Opinion in Chemical Biology, 2013The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J. Watts, Mark S. Dennis
openaire +3 more sources
Science Translational Medicine, 2020
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy. Double trouble for tumors Bispecific antibodies, which have one arm that binds to a cancer cell antigen and
D. Skokos +46 more
semanticscholar +1 more source
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy. Double trouble for tumors Bispecific antibodies, which have one arm that binds to a cancer cell antigen and
D. Skokos +46 more
semanticscholar +1 more source
Bispecific antibodies for the treatment of hemophilia A
Expert Opinion on Biological Therapy, 2021Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire +3 more sources